Brachytherapy
Brachytherapy 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Locally Advanced Cervical Adenocarcinoma、Locally Advanced Cervical Adenosquamous Carcinoma、Locally Advanced Cervical Squamous Cell Carcinoma、Stage IIIA Cervical Cancer FIGO 2018。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
1 项
已进入 III/IV 期
16 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- National Cancer Institute (NCI)
- Seoul National University Bundang Hospital
- Fujun Zhang
- IRCCS San Raffaele
- CivaTech Oncology
- Stanford University
- ARNAS Civico Di Cristina Benfratelli Hospital
- Aaron Wolfson
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
South Korea、中国、意大利、美国、加拿大、法国、Israel、India、日本、Thailand、丹麦、澳大利亚
正在招募患者的 Brachytherapy 研究
Intra-lesional Tumor Boost for Bulky Cervical Cancer
II 期招募中South KoreaNCT07435376Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
II 期招募中中国NCT0589401824 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer
不适用招募中意大利NCT05936736Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
II 期招募中美国NCT03290534Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).
II 期招募中美国NCT07022470a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer
不适用招募中意大利NCT06360653Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
I 期招募中美国NCT05603910SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
不适用招募中中国NCT06909708Toripalimab Combined With Definitive CCRT for LACC Patients
不适用招募中中国NCT06256224Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
不适用招募中加拿大NCT06508567Post-TRaUmatic STress Disorder Induced by Gynecological Brachytherapy
不适用招募中法国NCT07204535Serplulimab for Locally Advanced Cervical Cancer
II 期招募中中国NCT07340489Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
不适用招募中美国NCT04725903Optimizing Prostate Cancer Treatment in Men With Advanced Local Disease
不适用招募中加拿大NCT03836196Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors
不适用招募中IsraelNCT05781555Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
III 期招募中美国NCT01492972Asian Gynecological Brachytherapy Registry in Cervical Cancer
不适用招募中India日本ThailandNCT07196033Salvage HDR for Locally Recurrent Prostate Cancer
不适用招募中丹麦NCT04231006Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer
II 期招募中South KoreaNCT07439497Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer
不适用招募中中国NCT07904182Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
II 期招募中美国澳大利亚加拿大法国NCT05640999Hypofractionated WPPT With HDR Boost
II 期招募中美国NCT06591819Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
不适用招募中美国NCT06910306Clinical Feasibility of the ARCHITECT Applicator in Cervical Cancer Brachytherapy
不适用招募中荷兰NCT07435987
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。